The latest announcement is out from Disc Medicine (IRON).
Disc Medicine, Inc. announced significant progress in their clinical trials at the European Hematology Association 2024 Congress, showcasing promising data for their drugs bitopertin, DISC-0974, and DISC-3405, aimed at treating erythropoietic protoporphyria and myelofibrosis anemia. Bitopertin demonstrated substantial benefits in light tolerance and reduced phototoxic reactions for EPP patients, while DISC-0974 showed improved hemoglobin levels in myelofibrosis anemia patients. Initial data for DISC-3405 also revealed a potential for reducing serum iron in healthy volunteers. The company will share these insights during a live webcast, with further details available on their website.
For detailed information about IRON stock, go to TipRanks’ Stock Analysis page.
